Nystatin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Oral candidiasis In patients with denture sores or oral infections caused by Candida albicans: As susp: 100,000 units 4 times/day, higher doses of 400,000-600,000 units 4 times/day may also be given as necessary. Keep in contact with affected areas for as long as possible before swallowing. Treatment duration: Generally, 7-14 days or continue treatment for at least 48 hours after clinical cure is achieved to prevent relapse. Intestinal candidiasis Treatment: As susp: 500,000 units 4 times/day; swish and retain in the mouth and kept in contact with the affected area for as long as possible before swallowing. As tab/cap: 500,000-1,000,000 units 3 or 4 times/day. Prophylaxis: As susp/tab: 1,000,000 units/day. Continue treatment for at least 48 hours after clinical cure is achieved to prevent relapse. Topical Cutaneous or mucocutaneous mycotic infections As cream/ointment/dusting powder: Apply to the affected area bid or as clinically indicated until healing is complete. Vag Vulvovaginal candidiasis As pessary: 100,000-200,000 units/day preferably at bedtime for 14 consecutive days or longer. As vaginal cream: Apply 100,000 units (1 applicator-full) intravaginally 1 or 2 times daily for 14 days or longer. Continue treatment regardless of intervening menstruation.
Dosage Details
Oral
Oral candidiasis
Adult: In patients with denture sores or oral infections caused by Candida albicans: As susp: 100,000 units 4 times daily, higher doses of 400,000-600,000 units 4 times daily may also be given as necessary. Keep in contact with affected areas for as long as possible before swallowing. Treatment duration: Generally, 7-14 days or continue treatment for at least 48 hours after clinical cure is achieved to prevent relapse.
Child: As susp: Infant: 100,000 units 4 times daily, higher doses of 200,000 units 4 times daily (with ½ of the dose in each side of the mouth) may also be given as necessary. Keep in contact with affected area for as long as possible before feeding. Children: Same as adult dose. For prophylaxis of oral candidiasis in infants born of mothers with vaginal candidiasis: 100,000 units once daily.

Oral
Intestinal candidiasis
Adult: Treatment: As susp: 500,000 units 4 times daily; swish and retain in the mouth and kept in contact with the affected area for as long as possible before swallowing. As tab/cap: 500,000-1,000,000 units 3 or 4 times daily. Prophylaxis: As susp/tab: 1,000,000 units daily. Continue treatment for at least 48 hours after clinical cure is achieved to prevent relapse.
Child: Infant and children: As susp: 100,000 units into the mouth 4 times daily; swish and retain in the mouth and kept in contact with the affected area for as long as possible before swallowing.

Topical/Cutaneous
Cutaneous or mucocutaneous mycotic infections
Adult: As cream/ointment/dusting powder: Apply to the affected area bid or as clinically indicated until healing is complete.

Vaginal
Vulvovaginal candidiasis
Adult: As pessary: 100,000-200,000 units daily preferably at bedtime for 14 consecutive days or longer. As vaginal cream: Apply 100,000 units (1 applicator-full) intravaginally 1 or 2 times daily for 14 days or longer. Continue treatment regardless of intervening menstruation.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
Special Precautions
Immunocompromised patients. Oral preparations are not intended for the treatment of systemic mycoses. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions, irritation.
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain, gastrointestinal distress.
General disorders and administration site conditions: Application site reactions (e.g. pain, burning, itching).
Immune system disorders: Rarely, Steven-Johnson syndrome, urticaria.
Skin and subcutaneous tissue disorders: Rash, eczema, contact dermatitis.
Mouth/Throat/PO/Topical: C
Patient Counseling Information
Vaginal preparations may decrease the effectiveness of latex contraceptive agents (e.g. condoms, diaphragms).
Drug Interactions
May diminish therapeutic effects of Saccharomyces boulardii (oral), and progesterone (vaginal).
Action
Description: Nystatin interferes with the fungal cell wall permeability by binding to sterols in the fungal cell membrane, thereby allowing the leakage of cellular contents.
Onset: Symptomatic relief of candidiasis: 24-72 hours.
Pharmacokinetics:
Absorption: Poorly absorbed from the gastrointestinal tract (oral). Not absorbed through intact skin or mucous membrane (topical).
Excretion: Via faeces (as unchanged drug).
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C.
ATC Classification
D01AA01 - nystatin ; Belongs to the class of antibiotics. Used in the topical treatment of fungal infection.
A07AA02 - nystatin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
G01AA01 - nystatin ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
Disclaimer: This information is independently developed by MIMS based on Nystatin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Candistatin Skin Ointment
  • Mycostatin
  • Nystatin SM Pharma
  • Uphastatin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in